Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2023-08-04 Transaction in Own Shar…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (3 August 2023), including volume, highest, lowest, and VWAP prices. This directly corresponds to the definition of 'Transaction in Own Shares' (POS - Share Repurchase/Issuance). The RNS Number format also suggests a regulatory filing, but the content is highly specific to share transactions.
2023-08-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (2 August 2023), including volume, highest, lowest, and VWAP prices. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers the company buying back or selling its own shares.
2023-08-03 English
6-K
Transaction in Own Shares Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, PureTech Health plc, reporting on its share repurchase program activities during July 2023. It details daily purchases of the company's own shares under the program, including volumes and prices, and references regulatory compliance with UK and EU rules. The content focuses on the company's transactions in its own shares, specifically buybacks, rather than financial results, management changes, or other report types. The document length is 6543 characters, which is sufficient to contain substantive information about the share repurchase activity. Therefore, this filing is best classified as a Transaction in Own Shares (POS) report, which covers company buyback activities.
2023-08-02 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title: "Transaction in Own Shares" and details the purchase of ordinary shares as part of a "Share Buyback Programme." It provides specific transaction data (Date of purchase, Number of shares purchased, prices) and updates the total shares in treasury and in issue. This directly corresponds to the definition of a company reporting the purchase or sale of its own shares. Therefore, the correct classification is Transaction in Own Shares (POS).
2023-08-02 English
PRTC Gets $11.4M Grant for Ph2 of LYT-300 in FXTAS
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a specific corporate event: PureTech Health receiving funding from the U.S. Department of Defense to advance a therapeutic candidate (LYT-300). This is a material corporate update that is not a full financial report (like 10-K or IR), a transcript (CT), or a specific shareholder vote result (DVA). It is a general announcement of a significant business development. Since it is a formal regulatory announcement disseminated via RNS, and it doesn't fit the specific categories like ER (Earnings Release) or CAP (Capital/Financing Update, although funding is mentioned, the primary purpose is an R&D/clinical update announcement), the most appropriate general category for a material, non-standard announcement distributed through the RNS system is 'Regulatory Filings' (RNS), or potentially 'Capital/Financing Update' (CAP) if the funding aspect was dominant. However, given the structure (RNS Number, date, headline about R&D progress funded by DoD), it functions as a general regulatory disclosure. Since 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' and this is a specific operational/R&D update, RNS is the best fit as a catch-all for non-financial, non-governance regulatory news releases.
2023-08-01 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC dated August 1, 2023. The title explicitly states 'Transaction in Own Shares' and the content details the purchase of ordinary shares as part of a 'Share Buyback Programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers the company buying back or selling its own shares.
2023-08-01 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.